InsidersTradesSigma
Total declarations
Companies
▲ Purchases (22 ops.)
▼ Sales (4 ops.)
Explore the full record of transactions filed by RTW INVESTMENTS, LP, Board Member. Insider active across 4 companies, notably Rocket Pharmaceuticals, INC.. In total, 28 disclosures have been recorded. Total volume traded: €112.3m. The latest transaction was filed on 19 September 2025 — X. Regulator: SEC (Form 4). All data is openly available.
Declarations28 total
US$34m1,000,000 shares@ US$33.95159.57% mcap58.7% of flow
Common Stock
SEC:0001231919-25-000232·
€34m1,000,000 shares@ €33.95159.57% mcap29.3% of flow
Common Stock
SEC:0001231919-25-000232:0·
€311,57144,440 shares@ €7.0113.5% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000395·
Ideal exit: 15 Oct 2022 (T+270)
€311,57144,440 shares@ €7.0111.8% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000395:0·
Ideal exit: 15 Oct 2022 (T+270)
€13,1591,950 shares@ €6.74820.1% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000269·
Ideal exit: 9 Oct 2022 (T+270)
€13,1591,950 shares@ €6.74820.1% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000269:0·
Ideal exit: 9 Oct 2022 (T+270)
€283.932 shares@ €7.07820.0% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000093·
Ideal exit: 1 Oct 2022 (T+270)
€283.932 shares@ €7.07820.0% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000093:0·
Ideal exit: 1 Oct 2022 (T+270)
€3,387479 shares@ €7.07040.0% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000009·
Ideal exit: 25 Sept 2022 (T+270)
€3,387479 shares@ €7.07040.0% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-22-000009:0·
Ideal exit: 25 Sept 2022 (T+270)
€433,38761,584 shares@ €7.03734.9% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-005405·
Ideal exit: 19 Sept 2022 (T+270)
€433,38761,584 shares@ €7.03732.4% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-005405:0·
Ideal exit: 19 Sept 2022 (T+270)
€917,178129,516 shares@ €7.081610.3% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-005366·
Ideal exit: 16 Sept 2022 (T+270)
€917,178129,516 shares@ €7.08165.2% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-005366:0·
Ideal exit: 16 Sept 2022 (T+270)
€4,748600 shares@ €7.91260.1% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-005034·
Ideal exit: 12 Aug 2022 (T+270)
€4,748600 shares@ €7.91260.0% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-005034:0·
Ideal exit: 12 Aug 2022 (T+270)
€63,6928,949 shares@ €7.11730.7% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-004937·
Ideal exit: 6 Aug 2022 (T+270)
€63,6928,949 shares@ €7.11730.4% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-004937:0·
Ideal exit: 6 Aug 2022 (T+270)
€400,31157,914 shares@ €6.91224.5% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-004782·
Ideal exit: 1 Aug 2022 (T+270)
€400,31157,914 shares@ €6.91222.3% of flow
Common Stock, par value $0.0001 per share ("Common Stock")
SEC:0000902664-21-004782:0·
Ideal exit: 1 Aug 2022 (T+270)
€7m800,000 shares@ €8.4275.8% of flow
Common Stock, par value $0.0001 per share
SEC:0000919574-21-005731·
Ideal exit: 30 May 2022 (T+270)
€7m800,000 shares@ €8.4237.9% of flow
Common Stock, par value $0.0001 per share
SEC:0000919574-21-005731:0·
Ideal exit: 30 May 2022 (T+270)
€12m800,000 shares@ €15.2065.38% mcap100.0% of flow
Common Stock
SEC:0001826466-21-000107·
Ideal exit: 1 May 2022 (T+270)
€12m800,000 shares@ €15.2065.38% mcap50.0% of flow
Common Stock
SEC:0001826466-21-000107:0·
Ideal exit: 1 May 2022 (T+270)
€24m725,000 shares@ €32.96346.73% mcap41.3% of flow
Common Stock
SEC:0001493152-21-011359·
25 of 28 declarations
About RTW INVESTMENTS, LP
RTW Investments, LP is a life sciences investment and innovation firm with a significant presence in U.S. public markets, including NYSE- and NASDAQ-listed biotechnology and medtech companies. In its public materials, RTW describes itself as a full-lifecycle investor that can support companies from creation and early venture stages through crossover and public-market ownership. The firm emphasizes deep scientific research, long-term capital, and active company building, pairing scientific, financial, operational, and corporate-development capabilities to help portfolio companies advance important therapies for patients. Its publicly identified portfolio exposure includes Avidity Biosciences, Rocket Pharmaceuticals, Tarsus Pharmaceuticals, and Renovacor, reflecting a focus on areas such as gene therapy, RNA-based medicine, rare disease, and ophthalmology. ([rtwfunds.com](https://www.rtwfunds.com/about-us/?utm_source=openai)) Because RTW Investments, LP is an institutional investor rather than a conventional operating executive, public biographical information is better understood through its investment role and governance influence than through a single personal career path. Available sources show the firm acting as an active shareholder and strategic partner for biotechnology companies, with a stated capability to provide capital, transactional support, and board-level stewardship. RTW’s materials also highlight its long-term approach to value creation, including support for management teams, capital markets work, and corporate strategy across the company lifecycle. Since there is no public individual biography attached to the entity name itself, the safest accurate description is that RTW Investments, LP is best known as a specialized life sciences investor and governance participant, rather than as a single named executive with a traditional résumé. ([rtwfunds.com](https://www.rtwfunds.com/about-us/?utm_source=openai))
